Subscribe to our Newsletters !!
Few developments in science and technology have be
In modern pharmaceutical and laboratory settings,
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceuticals Limited (Alembic) today an
2026 marks a new chapter for the pharmaceutical an
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Novartis AG said on Thursday it had rejected the offer of its US dermatology and nonexclusive pill advantages for India’s Aurobindo Pharma Ltd subsequent to neglecting to get endorsement from a US controller.
Novartis said the choice to end the offer of Sandoz US’s nonexclusive oral solids and dermatology organizations was taken after the organizations didn’t get endorsement from the US Federal Trade Commission inside the foreseen courses of events.
The deal end comes around one and a half years after Novartis said it would sell the benefits for up to $1 billion to Aurobindo under Chief Executive Officer Vas Narasimhan’s arrangements to reshape the drugmaker.
Sandoz will keep on working the benefits as a major aspect of the Sandoz US business, the Swiss pharmaceutical mammoth said.
